Smoking has been linked with both increased and decreased risk of COVID-19, prompting the hypothesis of a protective role of nicotine in the pathogenesis of the disease. Studies of the association between use of smokeless tobacco and COVID-19 would help refining this hypothesis. We analysed data from 424,386 residents in the Stockholm Region, Sweden, with information on smoking and smokeless tobacco (snus) use prior to the pandemic obtained from dental records. Diagnoses of COVID-19 between February and October 2020 were obtained from health-care registers. We estimated the risk of receiving a diagnosis of COVID-19 for current smokers and for current snus users relative to non-users of tobacco, adjusting for potential confounders (aRR). The aRR of COVID -19 was elevated for current snus users (1.09 ;95%CI = 0.99–1.21 among men and 1.15; 95%CI = 1.00–1.33 among women). The risk for women consuming more than 1 can/day was twice as high as among non-users of tobacco. Current smoking was negatively associated with risk of COVID-19 (aRR = 0.68; 95% CI = 0.61–0.75); including hospital admission (aRR = 0.60; 95% CI = 0.47–0.76) and intensive care (aRR = 0.43; 95% CI = 0.21–0.89). The hypothesis of a protective effect of tobacco nicotine on COVID-19 was not supported by the findings. The negative association between smoking and COVID-19 remains unexplained.
The role of tobacco use in the incidence and prognosis of the coronavirus disease 2019 (COVID-19) has raised both scientific and public interest during the ongoing pandemic, due to contrasting findings reported so far in the scientific literature.
Early observations linked smoking to adverse prognosis of COVID-19 in Chinese patients1. Since then, studies have been published in several countries and repeatedly summarized in reviews and metanalyses, presenting a puzzling picture. On the one hand, smoking has been associated with a higher risk of adverse outcomes in COVID-19 patients admitted to hospital care. This roughly two-fold increased risk2 was generally in line with the previously established risk for respiratory complications caused by influenza virus3. However, a recent meta-analysis based on a progressive accrual of good and fair quality studies did not find an increased risk of COVID-19 among current compared with never smokers4. The same metanalysis also suggested that current smoking may be associated with a decreased risk of infection and/or symptomatic COVID-194. In fact, earlier studies already noted substantially lower proportions of smokers among patients hospitalized for COVID-19 compared with the underlying source population, even in studies where smoking predicted a poor prognosis of the disease5. Some studies also reported a lower prevalence of current smoking among individuals in out-of-hospital population samples who tested positive for SARS-CoV-2 infection compared to individuals who were negative6,7. Several explanations have been advanced for these negative associations, detracting from a causal hypothesis of smoking being protective against infection or disease caused by SARS-CoV-2. For instance, a negative association may appear due to selection bias, based on different characteristics (e.g., occupation) of individuals being tested and/or hospitalized. Information bias, due to under-ascertainment or under-report of smoking among hospitalized patients is another possibility8.
However, a causal link between smoking and a decreased risk of infection with SARS-CoV-2 and/or symptomatic COVID-19 has also been postulated, implying a protective role of nicotine in the pathogenesis of the disease. First, nicotine upregulates the angiotensin-converting enzyme 2 (ACE2) receptors in the lung, thus potentially increasing the virus entry points9. However, ACE2 receptors are also involved in the homeostatic regulation of the renin-angiotensin system (RAS), reducing the risk for pulmonary oedema and inflammation10. Recent studies even suggested that ACE2 can be suppressed by exposure to smoking11, for instance by activation of aryl-hydrocarbon receptor (AHR) due to polycyclic aromatic hydrocarbons12. Second, nicotine binding to the nicotine acetylcholine receptors (nAchR) in the lungs may downregulate the inflammatory response underlying the dramatic respiratory impairment typical of the disease (cytokine storm)13. It has also been proposed that nitric oxide (NO), a gas contained in the inhaled smoke, might have a toxic effect on the virus14. The hypothesized mechanisms remain speculative and lack empirical support in humans.
Given the public health importance of tobacco use as a risk factor for morbidity and mortality, but also of the potential therapeutic role of medicinal nicotine, it is very important that any claim of causality would rest on large population studies with low risk for bias, as also endorsed by the WHO15. One way to refine this hypothesis would be to analyze the association between smokeless tobacco use and COVID-19.
In Sweden, the use of the oral moist snuff known as snus is common16. This tobacco type doesn’t impact on the respiratory system but contains nicotine in the same concentration per gram of tobacco as cigarettes, albeit with a different profile of absorption17. Along with the lower level of restriction of use this makes the snus user potentially exposed to sustained high levels of nicotine. Therefore, we explored the association between tobacco use (cigarette smoking and the Swedish smokeless tobacco snus) and COVID-19 in a longitudinal study based on a historical cohort of clients of the public dental clinics in the region of Stockholm, Sweden.
Based on the a priori knowledge of the hazards connected to tobacco use, we hypothesized that:
the risk of COVID-19 and of severe cases requiring intensive care or resulting in death would be higher among current smokers than among current non-smokers; the risk of COVID-19 would not differ between current snus users and current non-users.
The study protocol of this retrospective cohort study was pre-registered at clinicaltrials.gov (NCT04896918, ID 4-1457/2021).
All methods were carried out in accordance with relevant guidelines and regulations.
The Ethical Review Authority of Sweden approved the study protocol, decision 2020-07152. In this decision, the requirement of individual informed consent was waived in accordance with the current practice of register-based research in Sweden handling unidentified personal information.
Study population and analytical sample
We identified a historical cohort of clients of public dental clinics in the Stockholm region. In Sweden, the public dental clinics (Folktandvården, FTV) routinely provide preventive visits (oral check-ups) to all residents who choose to receive care in these clinics. It is estimated that in the Stockholm region about 30% of the adult population of about 1.9 million inhabitants 18 years or older is enlisted in the 79 public clinics (the remaining being clients of private clinics). At each health check-up, self-reported information is collected on lifestyle and co-morbidities with relevance for oral health, with a uniform instrument in use since October 2015 (health declaration). Smoking and snus use is ascertained as past use, current use, and amount of current use. In late February 2020, the usual routine activity of the clinics was disrupted by the pandemic, and the oral health check-up was discontinued. We initially identified records corresponding to unique adult individuals accessing public dental clinics in the Stockholm Region between October 2015 to January 2020. Clients of these clinics are considered adults from the age of 23 years. Individuals accessing the clinics within seven months from the onset of the pandemic in Sweden (1st July 2019–31st January 2020), were considered to represent recent tobacco use experience, not likely to have changed before the pandemic. We used the national personal numbers assigned to every resident in Sweden at birth or at immigration to obtain information on diagnoses of COVID-19 and tobacco-related diseases among individuals in this cohort through record-linkage with the regional database of inpatient and outpatient health care (VAL database). Demographic information was extracted through record-linkage with the register of the total population of the region of Stockholm held by Statistics Sweden.
Only individuals with complete information on both smoking and snus use who could be linked to the regional registers were included in the analysis. Residents in assisted elderly dwellings were excluded because these individuals represent a segment of the population affected by multiple disabilities, very high mortality rates for all causes, and probably very low prevalence of tobacco use. After these exclusions, there were 424,386 individuals in the whole cohort (TOT-COH), of which 118,917 represented recent users (REC-COH). Figure 1 displays the flowchart of the analytical samples.
Exposure variables (current tobacco use)
Current tobacco use was reported in the dental clinic checklist separately for cigarette smoking and for snus use. It was analyzed both as a dichotomous variable (yes/no) and as a categorical variable of the originally reported average daily consumption (for cigarettes: no smoking, 10 cigarettes per day or less (CPD); 11–20 CPD; more than 20 CPD; for snus use: no use, less than 1/2 can per day; ½–1 can per day; more than 1 can per day).
Tobacco use was categorized as no current use; current exclusive smoking; current exclusive snus use; current mixed use (smoking and snus).
In a quality assessment, the variable corresponding to past tobacco use was found very incomplete because of inconsistent assessment; therefore it was not included in the analysis. This implies that former users of tobacco are included in the category of “current non-users”.
Outcome variables (diagnosis of COVID-19)
Information on the outcome was accrued for the period of February 25 -October 22, 2020.
Four outcome variables are included in the analysis:
Any diagnosis of COVID-19, whether in hospital or outside, consisting of at least a positive polymerase chain reaction test (PCR) reported by the laboratories to Sweden´s national electronic surveillance system for communicable diseases, SmiNet.
Hospital admission with a diagnosis of COVID-19 (ICD-10 codes U071 and U072). The diagnosis could be registered either as a main or as a concomitant diagnosis.
Admission to an intensive care unit (ICU) because of a diagnosis of COVID-19 (ICD-10 codes as above).
Death by COVID-19, established using the Swedish Cause of Death Registry, which is based on the death certificate filled in by physicians. All deaths occurring during the follow-up period with COVID-19 registered as the main cause were included. The restriction to main cause was done to maximize the specificity of the diagnosis18.
The outcome variables described above are not mutually exclusive, i.e., a includes b, c and d; b includes c and d; c includes at least some d; therefore any step can be conceptualized as a case of progression from infection with SARS-CoV-2 virus (see also Supplementary material Fig. 2).
Other variables included in the analysis as potential confounders or as moderators were:
Socio-demographic: gender; age; country of birth (Sweden; other Nordic country; other country); education (compulsory school, i.e., nine years of schooling; high school, i.e. 2 or 3 years of schooling after the compulsory education; university); occupation categorized as “high”, “moderate” or “low” risk of SARS-CoV-2 infection based on “a priori” knowledge on exposure to transmission of the virus; household disposable income in Swedish crowns—SEK per year; cohabitation with others (yes/no). We considered age, education, occupation, income, and cohabitation at the start of follow-up.
Chronic diseases that have been causally associated with tobacco use: any diagnosis of cancer, COPD, cardiovascular disease, diabetes mellitus, and Parkinson's disease up to February 25, 2020.
Risk ratios (RR) and their corresponding 95% CI were estimated through generalized linear models (GLM) for the binomial family with log link and the maximum likelihood optimization algorithm. The models were estimated for the following events: any diagnosis of COVID-19 (positive PCR test); hospitalization; admission to intensive care; and death because of COVID-19. These events were considered both in a cumulative fashion (i.e., “any diagnosis” includes even hospitalized, intensive care, and deaths) and as mutually exclusive events, i.e., extra-hospital diagnoses with non-lethal outcome; hospital diagnoses with no intensive care; intensive care surviving the disease; deaths. In the primary analyses, we separately compared current exclusive smokers or current exclusive users of snus with current non-users of any tobacco (reference). In a secondary analysis (sensitivity analysis), we also estimated the risk of COVID-19 among mixed tobacco users (those currently using both cigarettes and snus) compared with current non-users.
It should be noted that among these latter, some individuals may have been former tobacco users.
Because of missing information, the analysis of dose–response with reported tobacco consumption was based on slightly lower numbers of individuals.
Adjustments were made for putative confounders, namely age (in continuous form), gender, country of birth, type of employment, education, income (continuous), and cohabitation. The a priori consideration of the confounding structure is shown as directed acyclic graphs (DAGs) in Fig. S1 (Supplementary material), where different assumptions were made concerning the role of chronic diseases that have been causally associated with tobacco use (parts a and b). To explore possible effect modification due to different patterns of exposure and/or outcomes as well as for sensitivity analyses we conducted pre-registered separate analyses by age group (below 70 years of age or 70 years and above, cutoff chosen because of the sharp increase in mortality from COVID-19 after the age of 70; sex (in analyses of snus use); presence of chronic diseases causally associated with tobacco use; assumed infection risk associated with occupation (high vs. moderate and low); recency of assessment of tobacco use (more than 7 months or 7 months or less before the onset of the pandemic); and pandemic period (up to May 31, 2020; from June 1 until end of follow-up). This latter categorization corresponded to different strategies of virologic testing in Sweden, very restricted (only on medical prescription) in the first period, available on individual request thereafter. In a further sensitivity analysis, we used the national and regional incidence of PCR tests and the proportion of positive tests in the general population to estimate the expected number of smokers and non-smokers with a positive PCR test in the study cohort, under the null hypothesis of no difference in the risk of COVID-19. The expected and observed numbers were then compared to explore the extent of a potential under-ascertainment of COVID-19 among smokers. All analyses were performed with Stata version 16.1.
Baseline characteristics of cohort participants are shown in Table 1, separately for the whole sample (TOT-COH) and for the sample of individuals whose tobacco use was assessed during the 7 months immediately preceding the first case of COVID-19 (REC-COH).
Compared with the whole regional population, clients in public dental care were on average 3 years younger, with a higher proportion of women, individuals with university education, and Swedish born (Supplementary material Table S1). The proportion of current smokers was around 9% and that of snus users about 11%, in line with the proportions of daily smokers/snus users in previous regional or national surveys19. Most smokers smoked 10 cigarettes per day or less, with very few individuals smoking more than a pack per day. Among snus users, about 66% consumed less than half a can per day. There were no appreciable differences between the whole cohort of clients and the most recent clients (Table 1).
The cumulative incidence of COVID-19 diagnoses (1.5%) and of death (0.05%) were similar to the underlying regional population in the same period (1.2% and 0.09%, respectively), considering the age and sex differences.
Table 2 reports the distribution of incident COVID-19 diagnoses, hospital admissions, admission to ICU, and deaths across categories of current tobacco use. There were very few events in the category of mixed users, especially concerning hospital admission, intensive care, and deaths.
The risk of being diagnosed with COVID-19 throughout the study period was lower for current smokers relative to current non-users of tobacco, both before (not shown) and after adjustment for potential confounders (Table 3). Of note, the results were unchanged when the presence of chronic diseases (27% of the sample) was adjusted for (not shown). In addition, there was a hint of dose–response with decreasing risk associated with reported increasing consumption of cigarettes per day.
The associations were in the same direction for the incidence of hospital admission and admission to hospital intensive care, albeit in this latter case, the precision was low. The estimated relative risk of death for current smokers compared to non-user of tobacco was compatible with the hypothesis of no effect (RR 1.04, 95% CI 0.59–1.84).
In Table 4, the relative risk of COVID-19 diagnoses and death is shown for exclusive users of snus compared to non-users of tobacco, separately for women and men. Among men, there was an estimated 9% higher (95% CI = 0.99–1.21) risk of COVID-19 for current snus users vs non-users of tobacco. Among women snus users, there was a 15% higher risk (95% CI = 1.00–1.33), indeed two-fold higher among the minority consuming more than 1 can per day (adjusted RR 2.21, 95% CI = 1.17 -4.20). The associations with hospital admission, intensive care, or death were very imprecise in both sexes, and no further patterns were apparent.
The risk ratios for current mixed users of cigarettes and snus were similar to those for smokers (Supplementary Table S7).
When the outcome was analyzed in mutually exclusive categories of COVID-19 outcomes, similar patterns of associations were found. Among current smokers compared with non-users of tobacco, the adjusted risk ratio of a diagnosis of COVID-19 (positive PCR) that did not require hospital admission and did not cause death was 0.72 (95% CI 0.64–0.81); the corresponding aRR for hospital admission not requiring intensive care and not exiting in a death was 0.58 (95% CI 0.44–0.76); and for intensive care that was not followed by death was 0.46 (0.21–1.00).
Subgroup and sensitivity analyses
The results were virtually unchanged in the analysis of the cohort with more recent assessment of tobacco use (REC-COH) (Supplementary material Table S2).
The association between smoking and COVID-19 (all diagnoses and hospital admissions) was in the same direction as described in Table 3 in both time periods (up to May 31 or from 1 June 2020 on), although somewhat stronger during the early phase of the pandemic (Supplementary material Table S4).
Smoking was equally associated with a lower risk of any diagnosis and of hospital diagnosis with COVID-19 among individuals with or without previous diagnoses of chronic diseases causally associated with tobacco use (Supplementary material Table S6). In particular, the relative risk of hospital admission with COVID-19 was very low for smokers compared with non-users of tobacco among individuals without chronic diseases.
The number of smokers in the study cohort that was expected to be infected by SARS-CoV-2 or to develop COVID-19 during the study period, if they were tested with the same frequency as the general population, under the null hypothesis of no difference in risk was estimated as 414 (observed number 434, i.e., 4.4% higher). The same applied to non-smokers (expected 4257, observed 6116, i.e., 30.4% higher). Therefore, we estimated that the difference in the incidence of tests between smokers and non-smokers should have been larger than 25% to generate the observed risk ratios assuming no difference in true risk of COVID-19 between smokers and non-smokers, and even larger under the hypothesis of a higher risk among smokers.
In this large cohort accrued from clients of public dental services before the onset of the COVID-19 pandemic current smoking was associated with a decreased likelihood of being diagnosed with COVID-19, after adjustment for several potential confounders. Snus use, on the other hand, was associated with a higher risk of COVID-19 particularly among women heavy users. The risks of hospital admission and of intensive care because of COVID-19 followed the same patterns, while the risk of death was not associated with tobacco use in this cohort. The negative association between smoking and COVID-19 has been described. A very comprehensive meta-analysis that progressively summarizes new studies4 presented inference in line with that obtained in this study. To the best of our knowledge, an analysis of the Swedish smokeless tobacco (snus) use in relation to COVID-19 was previously reported only in an article from Finland20, with similar results. Snus is a tobacco product that is completely lacking an impact on the respiratory system but delivers substantial doses of nicotine to the user17. Therefore, the results of this study do not accord with the hypothesis of a beneficial role of nicotine in infection or disease caused by the SARS-CoV-2 virus. Nevertheless, the hypothesis of a role of nicotine in the risk of COVID-19 cannot be completely dismissed solely based on the positive association between snus use and COVID-19 presented in this study. The confounding structure of the association between snus and COVID-19 may be different from that hypothesized for smoking, and it is a possible explanation for the diverging associations. Another possibility is that the risk of infection and/or the prognosis of the disease among tobacco users could be mediated by characteristics or lifestyle that we could not explore in this study. For instance, high body mass index (BMI) has been implicated in the prognosis of COVID-1921, and BMI is on average lower among smokers than among non-smokers22 and higher among snus users than among non-users23. Also, the manipulation of the product requires frequent finger-mouth cavity contacts among snus users, which may expose them to the risk of infection. Unlike smoking, snus use is not forbidden indoors, and snus users are not perceived as individuals at risk of severe consequences of COVID-19. Therefore, they may be less discouraged than smokers from attending places where the risk of transmission is high (e.g., workplaces, and parties). It should be noted that during the pandemic period included in this analysis there were no stringent recommendations in Sweden concerning the use of face masks. Finally, the frequency of testing during the pandemic may be higher among snus users than in the general population, as was suggested in a parallel study from Norway (work submitted)24. All these factors may theoretically obscure a potential negative association between snus and COVID-19 due to nicotine. However, findings speaking against a protective role of oral tobacco or nicotine were also presented in other recent studies. In a cross-sectional study conducted in Indiana (USA), the prevalence of past or current infection with SARS-CoV-2 was higher among users than among non-users of chewed tobacco25. Nicotine did not show cytoprotective effects against SARS-CoV-2 in vitro assays26. In a clinical trial the use of medicinal nicotine as adjuvant treatment in COVID-19 patients admitted to intensive care units did not affect mortality27.
The conundrum of a possible causal negative association between current smoking and COVID-19 remains unanswered. Against this possibility speaks the counter-intuitive pathway linking a major hazard for the respiratory system to the decreased occurrence of a disease that has its major clinical expression in the same system28. The impact of a bias linked to differential referral to health care (e.g., virology test) among smokers compared with non-smokers cannot be excluded because in this cohort we did not have information on the incidence of testing. In previous studies, both higher4, lower29 or no different30 testing behavior among smokers compared with non-smokers have been described. In a related article based on a Norwegian cohort, there was no difference in self-reported testing behavior between smokers and non-smokers (work submitted)24.
Of note, in this population-based study, a lower (but not a higher) test opportunity among smokers compared with non-smokers (assuming no true risk difference) could result in a non-causal negative association between smoking and COVID-19, due to a relative under-ascertainment of COVID-19. Sensitivity analyses suggested indeed that the incidence of testing in this cohort may have been somewhat lower among smokers than among non-smokers. However, the magnitude of the under-ascertainment should be substantial to result in the negative association found in this data, especially in the case of a true higher incidence of the disease among smokers.
Also, the similarity of the results in two different periods of the pandemic, where testing strategies were completely different; and the similarity of the associations across stages of severity of the disease speak against a substantial bias introduced by testing opportunities.
Another possibility for a non-causal negative association between smoking and COVID-19 diagnoses may be a relatively lower sensitivity of the test of choice (SARS-CoV-2 RNA polymerase chain reaction) among current smokers31.
Finally, smokers may be protected from severe manifestations of the disease caused by SARS-CoV-2 because of their frequent exposure to other respiratory viruses, including other Coronaviruses, with consequent development of cross-immunity32.
Additional limitations should be kept in mind when interpreting the results from this study. We cannot rule out selection bias (for instance, if tobacco users and non-users in this cohort would be different from their counterparts in the source population because of factors differentially predicting the outcome). We could not explore whether specific mediators may account for the different association seen among smokers and snus users. Further, the analysis of former smokers (who have been found at higher risk for COVID-19)4 was not possible in this cohort. The lack of information on former smokers forced their inclusion in the reference category of “non-current tobacco use”, which may have contributed to a spurious lower risk observed for current smokers.
Notwithstanding these limitations the study has several strengths. First, it relies on a pre-registered analysis protocol, being part of an international consortium in the Nordic Countries20,24 triangulating the same scientific question33. Second, the large study cohort was population based, thus avoiding selection related to the ascertainment of the disease. Third, smoking and snus use were prospectively assessed with respect both to the disease outcome and to the onset of the pandemic, during which behavioral changes may have occurred. The exposure also included quantitative information on habitual consumption that allowed the study of dose–response. Fourth, the outcome was assessed through the regional surveillance system for COVID-19 and through health care registers, that have been checked for quality and uniformity of reports. In addition, COVID-19 outcomes could be studied according to indicators of disease progression and course, i.e., from out-of-hospital infection to death. Finally, we had the possibility to account for several confounders, among which the occupational and social risk of infection, rendering residual confounding less likely than in previous studies. A recent study from the UK employing both a traditional epidemiologic approach and a mendelian randomization analysis suggested indeed residual confounding as a likely explanation for the negative association smoking-COVID-1934.
We conclude that the purported causal protective effect of tobacco nicotine is not supported by the present study. The counter-intuitive lower risk of infection and of severe COVID-19 among smokers is still to be explained.
Individual information in this study is not publicly available but can be accessed with a research proposal and ethical clearance from the Swedish Ethical Review Authority. Meta-data and codebooks can be made available upon request to the corresponding author.
Liu, W. et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin. Med. J. 133, 1032 (2020).
Grundy, E. J., Suddek, T., Filippidis, F. T., Majeed, A. & Coronini-Cronberg, S. Smoking, SARS-CoV-2 and COVID-19: A review of reviews considering implications for public health policy and practice. Tob. Induc. Dis. 18, 58 (2020).
Han, L. et al. Smoking and influenza-associated morbidity and mortality: A systematic review and meta-analysis. Epidemiology 30, 405–417 (2019).
Simons, D., Shahab, L., Brown, J. & Perski, O. The association of smoking status with SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: A living rapid evidence review with Bayesian meta-analyses (version 12). Qeios https://doi.org/10.32388/UJR2AW.15 (2021).
Farsalinos, K., Barbouni, A. & Niaura, R. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: Could nicotine be a therapeutic option?. Intern. Emerg. Med. 15, 845–852 (2020).
de Lusignan, S. et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: A cross-sectional study. Lancet. Infect. Dis 20, 1034–1042 (2020).
Rentsch, C. T. et al. Covid-19 testing, hospital admission, and intensive care among 2,026,227 United States veterans aged 54–75 years. MedRxiv https://doi.org/10.1101/2020.04.09.20059964 (2020).
Cattaruzza, M. S., Zagà, V., Gallus, S., D’Argenio, P. & Gorini, G. Tobacco smoking and COVID-19 pandemic: Old and new issues. A summary of the evidence from the scientific literature. Acta Bio Medica Atenei Parmensis 91, 106 (2020).
Leung, J. M. et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: Implications for COVID-19. Eur. Respir. J. 55, 2000688 (2020).
Touyz, R. M., Li, H. & Delles, C. (Portland Press Ltd., 2020).
Tomchaney, M. et al. Paradoxical effects of cigarette smoke and COPD on SARS-CoV-2 infection and disease. BMC Pulm. Med. 21, 1–14 (2021).
Tanimoto, K. et al. Inhibiting SARS-CoV-2 infection in vitro by suppressing its receptor, angiotensin-converting enzyme 2, via aryl-hydrocarbon receptor signal. bioRxiv (2021).
Gauthier, A. G. et al. From nicotine to the cholinergic anti-inflammatory reflex–Can nicotine alleviate the dysregulated inflammation in COVID-19?. J. Immunotoxicol. 18, 23–29 (2021).
Hedenstierna, G., Chen, L., Hedenstierna, M., Lieberman, R. & Fine, D. H. Nitric oxide dosed in short bursts at high concentrations may protect against Covid 19. Nitric Oxide 103, 1–3 (2020).
World Health Organization. Smoking and COVID-19. https://www.who.int/news-room/commentaries/detail/smoking-and-covid-19 (2020).
Zetterqvist, M. & Ramstedt, M. Tobaksvanor i Sverige 2003–2019 [Tobacco use in Sweden 2003–2019] Centralförbundet för alkohol- och narkotikaupplysning, CAN.
Digard, H., Proctor, C., Kulasekaran, A., Malmqvist, U. & Richter, A. Determination of nicotine absorption from multiple tobacco products and nicotine gum. Nicotine Tob. Res. 15, 255–261 (2012).
Ioannidis, J. Over-and under-estimation of COVID-19 deaths. Eur. J. Epidemiol. 36, 581–588 (2021).
Bartelink, V. & Lager, A. (eds). Folkhälsorapport 2019. [Public Health Report 2019] Stockholm. Centrum för epidemiologi och samhällsmedicin, Region Stockholm (2019).
Peña, S. et al. Tobacco use and risk of COVID-19 infection in the Finnish general population. Sci. Rep. 12(1), 20335 (2022).
Ho, F. K. et al. Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: Results from a UK Biobank prospective cohort study. BMJ Open 10, e040402 (2020).
Engström, K., Magnusson, C. & Galanti, M. R. Socio-demographic, lifestyle and health characteristics among snus users and dual tobacco users in Stockholm County, Sweden. BMC Public Health 10, 1–10 (2010).
Hansson, J., Galanti, M. R., Magnusson, C. & Hergens, M.-P. Weight gain and incident obesity among male snus users. BMC Public Health 11, 1–8 (2011).
Caspersen, I. H. et al. Tobacco Use and Associations with SARS-CoV-2 Infection in Two Norwegian Cohorts. Submitted (Norwegian Institute of Public Health, 2021).
Duszynski, T. J. et al. Association of health status and nicotine consumption with SARS-CoV-2 positivity rates. BMC Public Health 21, 1–6 (2021).
Zheng, F. et al. Nicotine has no significant cytoprotective activity against SARS-CoV-2 infection. PLoS ONE 17(8), e0272941 (2022).
Labro, G. et al. Nicotine patches in patients on mechanical ventilation for severe COVID-19: A randomized, double-blind, placebo-controlled, multicentre trial. Intensive Care Med. 48(7), 876–887 (2022).
Hu, B., Guo, H., Zhou, P. & Shi, Z.-L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141–154 (2021).
Hopkinson, N. S. et al. Current smoking and COVID-19 risk: Results from a population symptom app in over 2.4 million people. Thorax 76, 714–722 (2021).
Ballering, A. V., Oertelt-Prigione, S., Initiative, L. C. R., olde Hartman, T. C. & Rosmalen, J. G. Sex and gender-related differences in COVID-19 diagnoses and SARS-CoV-2 testing practices during the first wave of the pandemic: The Dutch lifelines COVID-19 cohort study. J. Women's Health (2021).
Stockdale, A. J. et al. Sensitivity of SARS-CoV-2 RNA polymerase chain reaction using a clinical and radiological reference standard. J. Infect. 82, 260–268 (2021).
Sagar, M. et al. Recent endemic coronavirus infection is associated with less-severe COVID-19. J. Clin. Investig. 131, e143380 (2021).
Perski, O., Simons, D., Shahab, L. & Brown, J. Smoking, nicotine and COVID-19: Triangulation of methods and pre-registration are required for robust causal inference. Nicotine Tob. Res. https://doi.org/10.1093/ntr/ntab21 (2021).
Clift, A. K. et al. Smoking and COVID-19 outcomes: An observational and Mendelian randomisation study using the UK Biobank cohort. Thorax https://doi.org/10.1136/thoraxjnl-2021-217080 (2021).
This study was funded by NordForsk grant nr Tobrisk-Cov n. 105544. We gratefully acknowledge the contribution of the following persons and regional authorities that allowed access to and the use of the data: the Public Dentistry (Folktandvården) in the Stockholm Region; the Health and Medical Care administration of the Stockholm Region (Per Haglund); and the authority for communicable disease control (SMittskydd Stockholm, Joanna Nederby-Öhd).
Open access funding provided by Karolinska Institute. The study was funded by NordForsk grant Tobrisk-Cov n. 105544.
All coauthors apart from ANS are employed in the public health sector at the regional or national levels and affiliated to the corresponding academic institutions. None of the coauthors declares conflict of interest associated with commercial enterprises or non-financial competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Galanti, M.R., Andersson, F., Caspersen, I.H. et al. Current tobacco use and COVID-19 diagnoses in a cohort of adult clients of public dental clinics in Sweden. Sci Rep 13, 1204 (2023). https://doi.org/10.1038/s41598-023-28091-4
This article is cited by
BMC Public Health (2023)